- Tonix Pharmaceuticals Holding Corp to Host KOL Webinar TranscriptJan 31, 2024
- Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference TranscriptOct 19, 2023
- Tonix Pharmaceuticals Holding Corp At The June 1st Virtual Investor Summit TranscriptJun 01, 2023
- Tonix Pharmaceuticals Holding Corp At Investor Summit (Virtual) TranscriptMar 29, 2023
- Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio TranscriptFeb 23, 2023
- Tonix Pharmaceuticals Holding Corpinterview with Dr. Seth Lederman, MD, and CEO TranscriptFeb 13, 2023
- Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies TranscriptFeb 01, 2023
- Tonix Pharmaceuticals Holding Corp at EBD Group Biotech Showcase TranscriptJan 10, 2023
- Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference TranscriptOct 26, 2022
- Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit TranscriptMay 04, 2022
- Tonix Pharmaceuticals Holding Corp at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 27, 2022
- Tonix Pharmaceuticals Holding Corp at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 21, 2022
- Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) CEO & Investor Conference (Virtual) - Virtual Presentation TranscriptFeb 14, 2022
- Tonix Pharmaceuticals Holding Corp at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference TranscriptJan 14, 2021
- Tonix Pharmaceuticals Holding Corp Business Update TranscriptDec 07, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Network Virtual Conference TranscriptAug 06, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase TranscriptApr 29, 2020
- Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase TranscriptApr 22, 2020
- Tonix Pharmaceuticals Holding Corp at Tarsier Capital Management Spring Summit TranscriptMar 25, 2020
- Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference TranscriptFeb 18, 2020
Tonix Pharmaceuticals Holding Corp Business Update Transcript
Good morning, ladies and gentlemen and welcome to Tonix Pharmaceuticals Conference Call to discuss the result of the Phase 3 RELIEF study. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Peter Vozzo of Weswicke, Investor Relations for Tonix Pharmaceuticals. You may begin.
Thank you, [Jamie]. Good morning everyone and thank you for joining us today. We will review results of the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia. Early this morning, the company issued a press relief announcing the result of the study.
On the call with me today are Tonix Pharmaceuticals' President and Chief Executive Officer, Dr. Seth Lederman and Chief Medical Officer, Dr. Greg Sullivan. Today's call is being made available via the Investor Relations section of the company's website at ir
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)